Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depression and analgesia.
For use during the induction and maintenance of general anesthesia.
Ajou University Hospital, Suwon, Gyeonggi-do, Korea, Republic of
University Medical Centre Ljubljana, Ljubljana, Slovenia, Ljubljana, Slovenia
Department of Anaesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of
Zhongshan ophthalmic center, Sun Yat-sen University, Guangzhou, Guangdong, China
Fédération d'anesthésie-réanimation - Hôpital Pontchaillou, CHU de Rennes, Rennes, France
Service d'anesthésie-réanimation - Fondation A. de Rothschild, Paris, France
Département d'anesthésie-réanimation - Hôpital de la Cavale Blanche, CHU de Brest, Brest, France
Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Korea, Republic of
Ajou universiry hospital, Suwon, Gyeonggi-do, Korea, Republic of
KK Women's and Children's Hospital, Singapore, Singapore
Ankara University, Ankara, Turkey
Harran University, Sanliurfa, Turkey
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.